Key clinical point: Psoriasis is associated with a slightly increased risk of certain cancers, notably keratinocyte cancer and lymphoma.
Major finding: Psoriasis patients had an overall cancer prevalence of 4.78% and a risk ratio of 1.21, compared with controls.
Study details: The data come from a systematic review and meta-analysis of 112 studies that included 2,053,932 patients.
Disclosures: The study received no outside funding. Lead author Dr. Vaengebjerg had no financial conflicts to disclose. Several coauthors disclosed relationships with multiple companies, including AbbVie, Janssen, Novartis, Eli Lilly, LEO Pharma, UCB, Almirall, and Sanofi.
Vaengebjerg S et al. JAMA Dermatol. 2020 Feb 19. doi:10.1001/jamadermatol.2020.0024.